 |
Asparaginase |
  |
ATC : L01XX02 |
|
Carboplatin |
|
Paraplatin (Great Britain, Italy, Spain, Belgium, Austria, Switzerland, Denmark, Greece, Hungary, Norway, Netherlands, Poland, Sweden, Finland, United States of America, Mexico, Luxembourg, United Arab Emirates)
Paraplatine (France, Tunisia, Morocco)
ATC : L01XA02 |
|
Cefuroxime sodium |
 |
Ximaract (Great Britain, Spain, Belgium)
ATC : J01DC02 |
|
Clofarabine |
|
Clofarabin (Germany)
Clofarabina (Spain, Chile)
Clofarabine (France, Great Britain, Italy, Sweden, Finland)
Klofarabine (Croatia)
ATC : L01BB06 |
|
Clonidine hydrochloride |
 |
Paracefan (Germany)
ATC : C02AC01 |
|
Cytarabine |
|
Ara Cell (Germany, Portugal)
Arabine (Denmark, Sweden, Finland, Iceland)
Aracytin (Italy, Brazil, Egypt, Greece, Chile, Colombia)
Aracytine (France, Colombia, Morocco)
Citarabina (Italy, Spain, Argentina, Mexico, Chile, Colombia, Ecuador)
Cytarabine (Great Britain, Belgium, Australia, Canada, Egypt, Finland, United States of America, Ireland, New Zealand, Malaysia, United Arab Emirates)
Cytarax (Brazil, Mexico)
Ifarab (Mexico)
Laracit (Mexico, Chile, Colombia)
Medsara (Mexico)
ATC : L01BC01 |
|
Dacarbazine |
|
Daracina (Colombia)
ATC : L01AX04 |
|
Daratumumab |
|
ATC : L01FC01 |
|
Daunorubicin/cytarabine liposomale |
|
ATC : L01XY01 |
|
Fludarabine phosphate |
|
Fludara (France, Germany, Great Britain, Italy, Belgium, Austria, Switzerland, Denmark, Egypt, Hungary, Netherlands, Portugal, Poland, Romania, Sweden, Finland, United States of America, Ireland, Luxembourg, Iran, Saudi Arabia, New Zealand, Chile, Venezuela, India, Colombia, Malaysia)
Fludarabin (Italy, Switzerland, Norway, Sweden, Iceland)
Fludarabina (Spain, Argentina, Romania, Colombia, Peru)
Fludarabine (Belgium, Canada, Switzerland, Norway, United States of America, Iran, New Zealand)
ATC : L01BB05 |
|
Formoterol fumarate |
  |
ATC : R03AC13 |
|
Gentamicin sulfate |
|
Garalone (Portugal)
Garamicina (Brazil, Mexico, Colombia, Ecuador)
Garamycin (Switzerland, Denmark, Egypt, Greece, Norway, Netherlands, Poland, Croatia, India, United Arab Emirates)
ATC : J01GB03 |
|
Heparin sodium |
 |
Arapin (Chile)
ATC : B01AB01 |
|
Idarubicin hydrochloride |
|
Idaralem (Colombia)
ATC : L01DB06 |
|
Ketorolac tromethamine |
 |
Taradyl (Belgium, Luxembourg)
ATC : M01AB15 |
|
Metaraminol |
 |
Metaraminol 0.5 mg/ml solution for injection (Great Britain, Australia, Argentina, United States of America, Ireland, New Zealand)
ATC : C01CA09 |
|
Naratriptan Hydrochloride |
  |
ATC : N02CC02 |
|
Nelarabine |
|
ATC : L01BB07 |
|
Paracetamol |
 |
Axapara (Ecuador)
Paraconica (Switzerland)
Parasedol (Turkey)
ATC : N02BE01 |
|
Paracetamol |
|
ATC : N02BE01 |
|
Paracetamol |
 |
ATC : N02BE01 |
|
Quetiapine fumarate |
|
ATC : N04AH04 |
 |
26 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags. |
|
31 |
Hosp Pharm |
Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott’s B solution. |
|
76 |
Am J Hosp Pharm |
Stability of ganciclovir sodium in 5% dextrose injection and in 0.9% sodium chloride injection over 35 days. |
|
142 |
Am J Hosp Pharm |
Stability of fluorouracil, cytarabine, or doxorubicin hydrochloride in ethylene vinylacetate portable infusion-pump reservoirs. |
|
152 |
Pharm Acta Helv |
Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. |
|
215 |
Ann Pharmacotherapy |
Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. |
|
246 |
Aust J Hosp Pharm |
The stability of foscarnet in the presence of potassium. |
|
305 |
Am J Hosp Pharm |
Stability and sorption of calcitriol in plastic tuberculin syringes. |
|
410 |
Am J Hosp Pharm |
Characterization of cisplatin degradation as affected by pH and light. |
|
453 |
Am J Hosp Pharm |
Stability and availability of cyclosporine stored in plastic syringes. |
|
454 |
Am J Hosp Pharm |
Stability and availability of cyclosporine in 5% dextrose injection or 0.9% sodium chloride injection. |
|
455 |
Am J Hosp Pharm |
Leaching of diethylhexyl phtalate from polyvinyl chloride bags into intravenous cyclosporine solution. |
|
460 |
Am J Hosp Pharm |
Stability of acetazolamide sodium in 5% dextrose and 0.9% sodium chloride injection. |
|
475 |
Am J Hosp Pharm |
Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. |
|
492 |
Am J Hosp Pharm |
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. |
|
499 |
Hosp Pharm |
Intramuscular antibiotic preparation and administration using a 1% lidocaine diluent: policies for the pediatric patient. |
|
567 |
Can J Hosp Pharm |
Stability of clindamycin phophate in dextrose and saline solutions. |
|
643 |
Cancer Treat Rep |
In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. |
|
693 |
J Clin Pharm Ther |
Chemical stabilities of famotidine and ranitidine hydrochloride in intravenous admixtures. |
|
712 |
Am J Hosp Pharm |
Compatibility of diazepam with intravenous fluid containers and administration sets. |
|
739 |
Am J Hosp Pharm |
Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. |
|
753 |
Medac |
Topotecan (Topotecan Medac®) - Summary of Product Characteristics |
|
754 |
Merck Sharp & Dohme |
Infliximab (Remicade®) – Summary of Product Characteristics |
|
755 |
MSD France |
Pancuronium (Pavulon®) - Résumé des caractéristiques du produit |
|
789 |
Am J Hosp Pharm |
Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system. |
|
794 |
Anaesthesia |
The effect of the addition of lignocaine on propofol emulsion stability. |
|
815 |
Am J Health-Syst Pharm |
Stability of ondansetron hydrochloride and 12 medications in plastic syringes. |
|
844 |
J Pharm Clin |
Stability of fluorouracil and cytarabine in ethylvinylacetate containers. |
|
850 |
Drug Intell Clin Pharm |
Cytosine arabinose stability in intravenous admixtures with sodium bicarbonate and in plastic syringes. |
|
871 |
Anesth Analg |
The chemical stability and sterility of sodium thiopental after preparation. |
|
934 |
Int J Pharm Compound |
Compatibility and stability of ranitidine hydrochloride with six cephalosporins during simulated Y-site administration. |
|
978 |
Can J Hosp Pharm |
Methotrexate and cytarabine for intrathecal administration. |
|
1028 |
Am J Hosp Pharm |
Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. |
|
1055 |
Can J Hosp Pharm |
Compatibility of antibiotics and other drugs in total parenteral nutrition solutions. |
|
1061 |
Am J Health-Syst Pharm |
Urokinase after freezing : Implications for thrombolysis in intraventricular hemorrhage. |
|
1069 |
Am J Health-Syst Pharm |
Stability and compatibility of promethazine hydrochloride and dihydroergotamine mesylate in combination. |
|
1108 |
Crit Care Med |
Loss of nitroglycerin to cardiopulmonay bypass apparatus. |
|
1229 |
Br J Pharm Pract |
Chemical stability of cytarabine and vinblastine injections. |
|
1467 |
Int J Pharm |
Stability and compatibility of baclofen and morphine admixtures for use in an implantable infusion pump. |
|
1509 |
Norgine |
Dantrolene sodium (Dantrium®) - Summary of Product Characteristics |
|
1512 |
Beacon Pharmaceuticals Ltd |
Tirofiban (Aggrastat®) - Summary of Product Characteristics |
|
1513 |
Monarch Pharmaceuticals Ireland |
Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit |
|
1514 |
Novartis Pharmaceuticals UK Ltd |
Verteporfin (Visudyne®) – Summary of Product Characteristics |
|
1516 |
Mercury Pharmaceuticals Limited |
Ropivacaine (Naropeine®) - Summary of Product Characteristics |
|
1517 |
Sanofi-Aventis |
Rasburicase (Fasturtec®) - Summary of Product Characteristics |
|
1518 |
Hospira UK Ltd |
Raltitrexed (Tomudex®) - Summary of Product Characteristics |
|
1519 |
Merck Sharp Dohme |
Caspofungine (Cancidas®) - Summary of Product Characteristics |
|
1600 |
Am J Health-Syst Pharm |
Stability of tirofiban hydrochloride in 0.9% sodium chloride injection for 30 days. |
|
1661 |
J Oncol Pharm Practice |
Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott’s B Solution for intrathecal use. |
|
1678 |
Int J Pharm |
Stability and compatibility of intrathecal admixtures containing baclofen and high concentrations of morphine. |
|
1752 |
Int J Pharm Compound |
Stability of sufentanil in a syringe pump under simulated epidural infusion. |
|
1832 |
Pharmazie |
Stability of fentanyl/ropivacain preparations for epidural application. |
|
1835 |
Eur J Pharm Sci |
Stability of sufentanil and levobupivacain solutions and a mixture in a 0.9% sodium chloride infusion stored in polypropylene syringes. |
|
1858 |
Pharm Acta Helv |
Stability of L-asparaginase: an enzyme used in leukemia treatment. |
|
1863 |
Journal of clinical anesthesia |
Compatibility of propofol, fentanyl,and vecuronium mixtures designed for potential use in anesthesia and patient transport. |
|
1903 |
Am J Obstet Gynecol |
Oxytocin preparation stability in several common obstetric intravenous solutions. |
|
1911 |
Janssen-Cilag Ltd |
Bortezomib (Velcade®) - Summary of Product Characteristics |
|
1912 |
Merck Sharp Dohme |
Ertapenem (Invanz®) - Summary of Product Characteristics |
|
1913 |
Pfizer Europe |
Gemtuzumab ozogamicin (Mylotarg® - Summary of Product Characteristics) |
|
1914 |
Eli Lilly |
Pemetrexed (Alimta®) - Summary of Product Characteristics |
|
1915 |
Genzyme |
Imiglucerase (Cerezyme®) -Summary of product Characteristics |
|
1949 |
Clinical Cancer Research |
Phase I trial of 96 hour continuous infusion of dexrazoxane in patients with advanced malignancies. |
|
1956 |
Hospira UK Limited |
Paclitaxel - Summary of Product Characteristics |
|
1966 |
Support Care Cancer |
Stability and compatibility of binary mixtures of morphine hydrochloride with hyoscine-n-butyl bromide. |
|
1968 |
Hosp Pharm Pract |
Stability of morphine and droperidol separately and combined, for use as an infusion. |
|
1970 |
Support Care Cancer |
Compatibility of haloperidol and hyoscine-N-butyl bromide in mixtures for subcutaneous infusion to cancer patients in palliative care. |
|
1971 |
Support Care Cancer |
Physical compatibility and in vivo evaluation of drug mixtures forsubcutaneous infusion to cancer patients in palliative care. |
|
1978 |
Clin Ther |
Comparative sorption of clomipramine, viloxazine and maprotiline hydrochlorides in polyvinylchloride bags and glass vials. |
|
1985 |
Am J Health-Syst Pharm |
Stability of ibuprofen in injection solutions. |
|
2024 |
J Pain Symptom Manage |
Stability of tramadol and haloperidol for continuous infusion at home. |
|
2042 |
Antimicrob Agents Chemother |
Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). |
|
2055 |
Int J Pharm |
Morphine, haloperidol and hyoscine N-butyl bromide combined in sc infusion solutions : compatibility and stability evaluation in terminal oncology patients. |
|
2093 |
Shionogi B.V. |
Cefiderocol (Fetcroja®)- Summary of Product Characteristics |
|
2105 |
Farm Hosp |
Estabilidad de una mezcla de etomidato y pentotal para administracion intravenosa en bolo. |
|
2113 |
Pharm World Sci |
Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. |
|
2116 |
Am J Health-Syst Pharm |
Visual compatibility of furosemide with phenylephrine and vasopressine. |
|
2122 |
EJHP Science |
Stability and compatibility of paracetamol injection admixed with ketoprofen. |
|
2134 |
J Pharm Sci |
Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions. |
|
2140 |
EJHP Science |
Stability and compatibility of the ready-to-use solution of paracetamol admixted with phloroglucinol for intravenous infusion. |
|
2141 |
J Antimicrob Chemother |
Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. |
|
2148 |
Anal Biochem |
Analytical validation of a microplate reader-based method for the therapeutic drug monitoring of L-asparaginase in human serum. |
|
2163 |
Perit Dial Int |
Linezolid stability in peritoneal dialysis solutions. |
|
2176 |
Support Care Cancer |
Tramadol and hyoscine N-butyl bromide combined in infusion solutions: compatibility and stability. |
|
2181 |
Bull Cancer |
Etude de compatibilité physicochimique 5- fluoro-uracile (nouvelle préparation française) - acide folinique. |
|
2199 |
Mundipharma |
Chlorhydrate d'oxycodone (Oxynorm®)– Résumé des caractéristiques du produits |
|
2202 |
Investig Clin Farm |
Estabilidad de parecoxib en dilucion con ostros farmacos y administrado en perfusion continua IV para el control del dolor postoperatorio. |
|
2205 |
Arzneimittel Forschung |
Compatibility and stability of furosemide and dexamethasone combined in infusion solutions. |
|
2211 |
J Clin Pharm Ther |
Compatibility and stability of tramadol and dexamethasone in solution and its use in terminally ill patients. |
|
2212 |
Actavis UK Ltd |
Reteplase (Rapilysin®) - Summary of Product Characteristics |
|
2226 |
Pfizer Ltd |
Temsirolimus (Torisel®) - Summary of Product Characteristics |
|
2238 |
Baxter |
Clinomel - Résumé des caractéristiques du produit |
|
2240 |
Janssen Pharmaceuticals |
Décitabine (Dacogen®) - Summary of Product caracteristics |
|
2271 |
Novartis |
Daptomycine (Cubicin®) Résumé des caractéristiques du produits |
|
2272 |
Genzyme |
Clofarabine (Evoltra®) – Résumé des caractéristiques du produits |
|
2276 |
Pharma Mar SA |
Trabectedine (Yondelis®) - Summary of Product Characteristics |
|
2277 |
GlaxoSmithKline |
Argatroban - Summary of Product Characteristics |
|
2284 |
Astra Zenaca |
Esomeprazole sodium (Nexium IV®) – Summary of Product Characteristics |
|
2288 |
Cephalon |
Bendamustine hydrochloride (Treanda®) – Summary of Product Characteristics |
|
2295 |
Merck Sharp Dohme |
Fosaprepitant (Emend®) - Summary of Product Characteristics |
|
2296 |
Eumedica |
Témocilline (Negaban®) - Résumé des caractéristiques du produit |
|
2328 |
Organon |
Sugammadex (Bridion®) – Résumé des caractéristiques du produits |
|
2348 |
Alexion Europe SAS |
Eculizumab (Soliris®) – Summary of Product Characteristics |
|
2387 |
Am J Health-Syst Pharm |
Stability of oral liquid preparations of tramadol in strawberry syrup and a sugar-free vehicle |
|
2389 |
Am J Health-Syst Pharm |
Characterization of an extemporaneous liquid formulation of lisinopril |
|
2406 |
Am J Health-Syst Pharm |
Stability of oral liquid preparations of tramadol in strawberry syrup and a sugar-free vehicle |
|
2446 |
Am J Health-Syst Pharm |
Content uniformity and stability of nifedipine in extemporaneously compounded oral powders |
|
2500 |
Am J Hosp Pharm |
Stability of nizatidine in extemporaneous oral liquid preparations |
|
2530 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Vancomycin 10-mg/mL Intravitreal Syringes. |
|
2543 |
Ann Pharmacotherapy |
Stability of mycophenolate mofetil as an extemporaneous suspension.
|
|
2567 |
Pakistan J Biol Sci |
Preparation and stability study of diclofenac sodium suppositories. |
|
2678 |
Int J Pharm Compound |
Naratriptan hydrochloride in extemporaneously compounded oral suspensions. |
|
2683 |
Int J Pharm Pract |
Shelf life of cefuroxime eye-drops when dispensed in artificial tear preparations. |
|
2692 |
J Am Pharm Assoc |
Preparation and stability of extemporaneous oral liquid formulations of oseltamivir using commercially available capsules. |
|
2697 |
J Clin Pharm Ther |
The formulation and stability of a unit-dose oral vitamin K1 preparation. |
|
2786 |
Am J Health-Syst Pharm |
Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. |
|
2810 |
Antimicrob Agents Chemother |
Preparation and stability of voriconazole eye drop solution. |
|
2836 |
Int J Pharm Compound |
Stability of Hydralazine Hydrochloride in Both Flavored and Nonflavored Extemporaneous Preparations |
|
2838 |
Pierre Fabre |
Vinflunine (Javlor®) – Résumé des caractéristiques du produits |
|
2852 |
Int J Pharm Compound |
Stability of Extemporaneous Oral Ribavirin Liquid Preparation |
|
2864 |
Astellas Pharma |
Isavuconazonium (Cresemba®) - Summary of Product Characteristics |
|
2894 |
J Dermatolog Treat |
A topical azythromycin preparation for the treatment of acne vulgaris and rosacea. |
|
2902 |
Forrest Pharmaceuticals |
Ceftazidime - avibactam (Avycaz®) - Summary of Product Characteristics |
|
2986 |
J Clin Pharm Ther |
Chemical stabilities of isoetharine hydrochloride, metaproterenol sulphate and terbutaline sulphate after mixing with normal saline for respiratory therapy. |
|
2990 |
Roche |
Trastuzumab Emtansine (Kadcyla®) - Summary of Product Characteristics. |
|
2998 |
J Pharm Technol |
Preparation and stability of an oral suspension of dipyridamole. |
|
3077 |
Roche |
Trastuzumab (Herceptin®) – Summary of Product Characteristics |
|
3084 |
Bristol Myers Squibb |
Ixabepilone (Ixempra®) – Summary of Product Characteristics |
|
3110 |
Poster ADKA Congress May 2010 |
Physikalisch-chemische Stabilität von Clofarabin-Zubereitungen. |
|
3117 |
Merck Sharp Dohme |
Temozolomide (Temodal ®) - Summary of Product Characteristics |
|
3128 |
Prostrakan |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit |
|
3129 |
Pfizer |
Irinotécan (Campto®) – Résumé des caractéristiques du produits |
|
3130 |
Sanofi Avantis France |
Docétaxel (Taxotere®) – Résumé des caractéristiques du produits |
|
3132 |
J Palliat Med |
Compatibility and stability of ternary admixtures of tramadol, haloperidol, and hyoscine. |
|
3134 |
Enferm Intensiva |
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. |
|
3138 |
GlaxoSmithKline |
Ofatumumab (Arzerra®) - Summary of Product Characteristics |
|
3142 |
SP Europe |
Doxorubicin hydrochloride liposome (Caelyx®) - Summary of Product Characteristics |
|
3143 |
Teva Laboratoire |
Doxorubicin hydrochloride liposome (Myocet®) - Summary of Product Characteristics |
|
3155 |
J Ocular Pharm Ther |
Stability of Fortified Cefazolin Ophthalmic Solutions Prepared in Artificial Tears Containing Surfactant-Based Versus Oxidant-Based Preservatives. |
|
3157 |
Celgene Europe Limited |
Paclitaxel albumin (Abraxane®) - Summary of Product Characteristics |
|
3158 |
Astellas Pharma GmbH |
Bendamustine (Levact®) - Summary of Product Characteristics |
|
3162 |
Bayer HealthCare |
Moxifloxacine (Izilox®) - Résumé des caractéristiques du produits |
|
3184 |
CP Pharmaceuticals |
Hyaluronidase (Hyalase®) - Summary of Product characteristics. |
|
3206 |
Int J Pharm Compound |
Nifedpine in Compounded Oral and Topical Preparations. |
|
3210 |
Int J Pharm Compound |
Compatibility of Parenteral Furosemide with Seventeen Secondary Drugs Used in Standard Concentrations. |
|
3225 |
EJHP Science |
Physico-chemical stability of nelarabine infusion solutions in EVA infusion bags. |
|
3236 |
Celgene |
Azacitidine (Vidaza®) - Résumé des caractéristiques du produit |
|
3237 |
Sanofi Aventis France |
Cabazitaxel (Jevtana®) - Résumé des caractéristiques du produit. |
|
3243 |
ECCO Congress Stockholm |
Stability of diluted L-asparaginase in normal saline solution. |
|
3250 |
Eisai Ltd |
Eribulin (Halaven®) - Summary of Product Characteristics. |
|
3260 |
Astellas Pharma Europe |
Telavancin (Vibativ®) - Summary of Products characteristics |
|
3261 |
Bristol Myers Squibb |
Belatacept (Nulojix®) – Résumé des caractéristiques du produit |
|
3267 |
Lipomed |
Dacarbazine Lipomed - Summary of Product Characteristics |
|
3275 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared cytarabine, methotrexate sodium, and methylprednisolone sodium succinate |
|
3295 |
LFB Biom?dicaments |
Argatroban - Résumé Caractéristiques du Produit |
|
3306 |
EJOP |
New stability studies for fludarabine according to the European Pharmacopoeia 7.0 |
|
3313 |
J Oncol Pharm Practice |
Long-term stability study of clofarabine injection concentrate and diluted clofarabine infusion solutions. |
|
3314 |
Bristol Myers Squibb |
Carmustine (Bicnu®) – Résumé des caractéristiques du produits |
|
3315 |
Communication orale Hopipharm |
Mise en évidence d'une incompatibilité physico-chimique entre la phénytoïne sodique et le paracétamol injectable en flacon. |
|
3320 |
CTI Life Sciences Limited |
Pixantrone (Pixuvri®) - Summary of Product Characteristics |
|
3332 |
Pfizer |
Tigecycline (Tigacyl®) - Summary of Product characteristics |
|
3337 |
EJHP |
Stability of bortezomib reconstituted under clinical use conditions in original vials and polypropylene syringes at 4 °C and room temperature. |
|
3341 |
Krankenhauspharmazie |
Ist teurer immer auch besser? Analytiklabor der Apotheke unterstütz Einkauf sentcheidungen bei Carboplatin-Präparaten. |
|
3348 |
Amgen |
Carfilzomib (Kyprolis®) - Résumé des caractéristiques du produit |
|
3352 |
Bristol Myers Squibb |
Ipilimumab (Yervoy®) - Summary of Product Characteristics |
|
3366 |
J Pharm Sci |
Compatibility and stability of pertuzumab and trastuzumab admixtures in i.v. infusion bags for coadministration. |
|
3369 |
MEDAC France |
Levofolinate de sodium Medac - Résumé des caractéristiques du produits |
|
3383 |
Farm Hosp |
Evaluación de la estabilidad de un jarabe de hidrato de cloral al 7% en envases mono y multidosis bajo condiciones ambiente y de refrigeración. |
|
3384 |
Farm Hosp |
Estudio de estabilidad de tiaprida en disolución para administración en perfusión intravenosa continua. |
|
3398 |
Gilead Science (France) |
Amphotéricine B (Ambisome®) - Résumé des caractéristiques du produit |
|
3401 |
J Clin Pharm Ther |
Stability of an epidural analgesic admixture of levobupivacaine, fentanyl and epinephrine. |
|
3407 |
Farm Hosp |
Suspensiones extratemporáneas de clobazam para uso pediátrico preparadas a partir de tabletas disponibles comercialmente y fármaco puro. |
|
3432 |
Celgene Corporation |
Romidepsin (Istodax®) - Summary of Product Characteristics |
|
3464 |
Enferm Clin |
Compatibilidad física de la amiodarona en perfusión continua |
|
3465 |
Enferm Intensiva |
Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. |
|
3474 |
Accord Healthcare Limited |
Fluorouracil - Summary of Product Characteristics |
|
3488 |
Farm Hosp |
Jarabe de midazolam: Estudio de estabilidad de una solucion oral para uso hospitaliaro. |
|
3495 |
Takeda |
Brentuximab (Adcetris®) - Summary of Product Characteristics |
|
3498 |
Ann Pharmacotherapy |
Compatibility and aerosol characteristics of formoterol fumarate mixed with other nebulizing solutions. |
|
3501 |
Pfizer |
Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics |
|
3502 |
Astra Zeneca |
Propofol (Diprivan®) - Summary of Products Characteristics |
|
3503 |
Hameln Pharmaceuticals |
Fentanyl - Summary of product Characteristics |
|
3504 |
Pfizer |
Parecoxib (Dynastat®) - Summary of Product Characteristics |
|
3507 |
AbbVie |
Chirocaine - Summary of Product Characteristics |
|
3508 |
Sanofi Aventis Group |
Aflibercept (Zaltrap®) - Summary of Product characteristics |
|
3519 |
Glaxo Smith Kline |
Remifentanil hydrochloride(Ultiva®) - Summary of Product Characteristics |
|
3521 |
Beacon Pharmaceuticals |
Tramadol® - Summary of Product Characteristics. |
|
3522 |
Actavis |
Flucloxacillin - Summary of Product Characteristics. |
|
3523 |
Roche |
Ceftriaxone (Rocephin®) - Summary of Product Characteristics. |
|
3524 |
Sanofi |
Amiodarone hydrochloride (Cordarone®) - Summary of Product Characteristics. |
|
3525 |
AMCO Amdipharm Mercury |
Pethidine hydrochloride - Summary of product Characteristics |
|
3526 |
Pharmacia |
Clindamycin (Dalacin®) - Summary of Product Characteristics |
|
3527 |
Glaxo Smith Kline |
Amoxicillin (Amoxil®) – Summary of Product Characteristics |
|
3528 |
Essential generics |
Ampicillin sodium – Summary of Product Characteristics |
|
3529 |
Hospira |
Ciprofloxacin – Summary of Product Characteristics |
|
3530 |
Hospira |
Imipenem/Cilastatin – Summary of Product Characteristics |
|
3531 |
Wockhardt |
Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics |
|
3539 |
The Medecines Company |
Bivalirudin (Angiox®) - Summary of Product Characteristics. |
|
3540 |
Wockhardt |
Heparin sodium - Summary of Product Characteristics. |
|
3541 |
Sanofi |
Rifampicin (Rifadin®) – Summary of Product Characteristics |
|
3543 |
Wockhardt |
Ceftazidime – Summary of Product Characteristics |
|
3544 |
Pfizer |
Cefoperazone (Cefobid®) - Summary of Product Characteristics |
|
3545 |
Mylan SAS |
Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit |
|
3546 |
Panpharma SA |
Cefamandole Flavelab - Résumé des caractéristiques du produit |
|
3547 |
Sanofi-Aventis France |
Aztréonam (Azactam®) - Résumé des caractéristiques du produit |
|
3548 |
Bristol Myers Squibb |
Cefepime (Maxipime®) - Summary of Product caracteristics. |
|
3549 |
B Braun |
Amikacine B Braun - Résumé des caractéristiques du produit. |
|
3559 |
Sanofi Aventis France |
Pentamidine diiséthionate (Pentacarinat®) - Résumé des caractéristiques du produit |
|
3560 |
Pharmacia |
Linezolid (Zyvox®) - Summary of Product Characteristics |
|
3562 |
Sanofi |
Ofloxacin (Tarivid®) - Summary of Product Characteristics |
|
3563 |
Sanofi Aventis France |
Spiramycine adipate (Rovamycine®) - Résumé des caractéristiques du produit |
|
3564 |
B Braun |
Rocuronium B Braun - Résumé des caractéristiques du produit. |
|
3565 |
Aguettant |
Flumazenil Aguettant - Résumé des caractéristiques du produit. |
|
3566 |
Pfizer |
Voriconazole (Vfend®) - Summary of Product characteristics. |
|
3567 |
Pfizer |
Anidulafungin (Ecalta®) - Summary of Product Characteristics. |
|
3573 |
Astellas |
Micafungin (Mycamine®) – Summary of Product Characteristics |
|
3574 |
Accord Healthcare France SAS |
Ondansetron - Résumé des caractéristiques du produit |
|
3575 |
Prostrakan |
Mitomycine (Ametycine®) - Résumé des caractéristiques du produit |
|
3576 |
Prostrakan |
Amsacrine (Amsalyo®) - Résumé des caractéristiques du produit |
|
3577 |
Galen Limited |
Daunorubicine (Daunoxome®) - Résumé des caractéristiques du produit |
|
3578 |
Accord Healthcare |
Cisplatin - Summary of Product Characteristics |
|
3579 |
Janssen Cilag |
Cladribine Janssen Cilag - Résumé des caractéristiques du produit |
|
3580 |
Accord Healthcare France |
Cytarabine Accord - Résumé des caractéristiques du produit |
|
3581 |
Clinigen Healthcare |
Dexrazoxane (Cardioxane®) - Résumé des caractéristiques du produit |
|
3583 |
Roche |
Sulfaméthoxazole triméthoprime (Bactrim®) - Résumé des caractéristiques du produit |
|
3584 |
Aspen Pharma |
Melphalan (Alkéran®) - Résumé des caractéristiques du produit |
|
3585 |
Genus Pharmaceuticals |
Benzylpenicillin sodium - Summary of Product Characteristics |
|
3586 |
Actavis France |
Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit |
|
3587 |
GlaxoSmithKline |
Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics |
|
3588 |
Sandoz |
Vancomycine (Vancocin®) - Résumé des caractéristiques du produit |
|
3589 |
PanPharma |
Oxacilline PanPharma – Résumé des caractéristiques du produits |
|
3590 |
Dakota Pharm |
Piperacilline - Résumé des caractéristiques du produit |
|
3591 |
Bristol Myers Squibb |
Amphotericine B (Fungizone®) - Résumé des caractéristiques du produit |
|
3592 |
Sandoz |
Cimetidine - Résumé des caractéristiques du produit |
|
3593 |
Beacon Pharmaceuticals |
Ketorolac trometamol (Ketorolac®) - Summary of Product Characteristics |
|
3594 |
Zentiva |
Metronidazole (Flagyl®) - Summary of Product Characteristics |
|
3595 |
Hospira |
Aciclovir - Summary of Product Characteristics |
|
3596 |
Sanofi |
Chlorpromazine (Largactil®) - Summary of Product Characteristics |
|
3597 |
AstraZeneca |
Terbutaline sulfate (Bricanil®) - Summary of Product Characteristics |
|
3598 |
Clinigen Healthcare Ltd |
Amifostine (Ethyol®) - Résumé des caractéristiques du produit |
|
3599 |
Amco Amdipharm Mercry |
Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics |
|
3600 |
UCB Pharma SA |
Hydroxyzine (Atarax®) - Résumé des caractéristiques du produit |
|
3601 |
Actavis |
Cisatracurium Actavis - Résumé des Caractéristiques du Produit |
|
3602 |
Baxter SAS |
Mesna (Uromitexan®)- Summary of Product Characteristics |
|
3603 |
Adienne Pharma Biotech |
Thiotepa (Tepadina®) - Summary of Product Characteristics |
|
3604 |
Sanofi Aventis France |
Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit |
|
3605 |
Lipomed |
Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit |
|
3606 |
Wokhardt |
Dobutamine - Summary of Product Characteristics |
|
3607 |
AOP Orphan Pharmaceuticals AG |
Esmolol hydrochloride for injection - Summary of Product Characteristics |
|
3609 |
Aspen Pharma |
Labetalol (Trandate®) - Summary of Product Characteristics |
|
3612 |
Amdipharm Mercury Company |
Doxapram (Dopram) - Summary of Product Characteristics |
|
3613 |
Primius Lab |
Dihydralazine (Nepressol®) - Résumé des caractéristiques du produit |
|
3614 |
American Regent Inc |
Nicardipine Injection - Summary of Product Characteristics |
|
3616 |
Boehringer Ingelheim |
Altéplase (Actilyse®) - Résumé des caractéristiques du produit |
|
3617 |
Wockhardt |
Hyaluronidase (Hyalase®) - Summary of Product Characteristics |
|
3618 |
Amgen |
Filgrastim (Neupogen®) - Summary of Product Characteristics |
|
3619 |
Wockhardt |
Pamidronate (Pamidronate Actavis®) - Summary of Product Characteristics |
|
3620 |
Beacon Pharmaceuticals |
Phenylephrine - Summary of Product Characteristics |
|
3621 |
Renaudin |
Phosphate dipotassique - Résumé des caractéristiques du produit |
|
3624 |
Int J Pharm Compound |
Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets. |
|
3625 |
CSL Behring |
Streptokinase (Streptase®) - Summary of Product Characteristics |
|
3626 |
Astellas Pharma |
Tacrolimus (Prograf®) - Résumé des Caractéristiques du Produit |
|
3627 |
Boeringer Ingelheim |
Tenecteplase (Metalyse®) - Summary of Product Characteristics |
|
3629 |
Actavis UK |
Atracurium (Atracurium solution for injection/infusion®) - Summary of Product Characteristics |
|
3630 |
Merck Sharp Dohme |
Vecuronium (Norcuron®) - Summary of Product Characteristics |
|
3631 |
Aguettant |
Suxamethonium (Suxamethonium Aguettant®) - Résumé des caractéristiques du produit |
|
3632 |
Hospira |
Epirubicine (Epirubicine Hospira®) - Summary of Product Characteristics |
|
3634 |
Accord Healthcare |
Oxaliplatine (Oxaliplatine Accord®) - Résumé des caractéristiques du produit |
|
3635 |
Novartis Pharmaceuticals UK Ltd |
Aldesleukine (Proleukin®) - Summary of Product Characteristics |
|
3637 |
Hameln Pharmaceuticals |
Methotrexate (Methotrexate solution for injection®) - Summary of Product Characteristics |
|
3638 |
Hospira |
Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics |
|
3639 |
Wockhardt |
Furosemide - Summary of Product Characteristics |
|
3640 |
Hospira |
Mitoxantrone - Summary of Product Characteristics |
|
3641 |
Pierre Fabre |
Vinorelbine (Navelbine®) - Summary of Product Characteristics |
|
3642 |
International Medication System (UK) |
Epinephrine - Résumé des Caractéristiques du Produit |
|
3643 |
Sanofi |
Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics |
|
3644 |
Hameln Pharmaceuticals |
Calcium gluconate® - Summary of Product Characteristics |
|
3645 |
Accord Healthcare |
Doxorubicin - Summary of Product Characteristics |
|
3646 |
Sanofi Aventis France |
Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit |
|
3647 |
Roche |
Trastuzumab (Herceptin® 600 mg for subcutaneous injection) - Summary of Product Characteristics |
|
3653 |
Laboratoire Léo |
Bumétanide (Burinex®) - Résumé des caractéristiques du produit |
|
3654 |
Keocyt |
Streptozocine (Zanosar®) - Résumé des caractéristiques du produit |
|
3655 |
Bristol Myers Squibb |
Etoposide phosphate (Etopophos®) - Résumé des caractéristiques du produit |
|
3656 |
Sanofi Aventis France |
Teicoplanine (Targocid®) - Résumé des caractéristiques du produit |
|
3658 |
Sandoz |
Omeprazole - Summary of Product Characteristics.
|
|
3659 |
AstraZeneca |
Propofol (Diprivan®) - Résumé des caractéristiques du produit |
|
3660 |
Hospira |
Isoprenaline (Isuprel®) - Résumé des caractéristiques du produit |
|
3661 |
Laboratoire Léo |
Fusidate de sodium (Fucidine®) - Résumé des caractéristiques du produit |
|
3662 |
Clinigen |
Foscavir (Foscarnet®) - Summary of Product Characteristics |
|
3663 |
Panpharma |
Fosfomycine (Fosfomycine Panpharma®) - Résumé des caractéristiques du produit |
|
3668 |
Hospira |
Dexamethasone - Summary of Product Characteristics |
|
3671 |
Teva UK Ltd |
Deferoxamine - Résumé des caractéristiques du produit |
|
3672 |
Mylan SAS |
Nalbuphine Mylan - Résumé des caractéristiques du produit |
|
3674 |
PanPharma |
Erythromycin lactobionate - Summary of Product Characteristics |
|
3675 |
Archimedes Pharma UK Ltd |
Thiopental sodium - Summary of Product Characteristics |
|
3676 |
Hospira |
Atracurium bésilate (Atracurium Hospira®) - Résumé des caractéristiques du produit |
|
3677 |
Sanofi Aventis France |
Cefpirome (Cefrom®) - Résumé des caractéristiques du produit |
|
3683 |
Aguettant |
Baclofen - Résumé des caractéristiques du produit |
|
3684 |
Laboratoire Léo |
Bumétanide (Burinex®) - Résumé des caractéristiques du produit |
|
3686 |
Eusapharma |
L asparaginase (Kidrolase®) - Résumé des caractéristiques du produit |
|
3687 |
Stravencon |
Cefuroxime sodium - Summary of Product Characteristics |
|
3701 |
Gentium SPa |
Defibrotide (Defitelio®) - Summary of Product Characteristics |
|
3706 |
Farm Hosp |
Estudio de estabilidad de oxaliplatino y doxorrubicina para su administración intraperitoneal con hipertermia. |
|
3708 |
ECOP 2 Krakow |
Compatibility of epirubicin-loaded DC Beads with different contrast media. |
|
3711 |
Takeda |
Vedolizumab (Entyvio®) - Summary of Product Characteristics |
|
3718 |
Bayer Healthcare Corporation |
Conivaptan (Vaprisol®) - Summary of Product Characteristics |
|
3721 |
Spectrum Pharmaceuticals |
Belinostat (Beleodaq®) - Summary of Product Characteristics |
|
3723 |
Archives de Pédiatrie |
Stabilité des préparations extemporanées de doxapram (Doprams®) à usage néonatal. |
|
3752 |
Durata Therapeutics Holding |
Dalbavancin (Dalvance®) - Summary of Product Characteristics |
|
3753 |
Cubist Pharmaceuticals |
Tedizolid phosphate (Sivextro®) - Summary of Product Characteristics |
|
3758 |
J Pharm Pract and Res |
Feasibility and stability of metaraminol in pre-filled syringes. |
|
3759 |
Yakugaku Zasshi |
Examination of the cause of changing solution color by mixing aminophylline and dopamine, the compatibility of which was indicated by the supplier. |
|
3768 |
Roche Products Limited |
Obinutuzumab (Gazyvaro®) - Summary of Product Characteristics |
|
3769 |
B Braun laboratoire |
Paracatamol (Paracetamol B Braun®) - Résumé des caractéristiques du produit |
|
3770 |
Eclat Pharmaceuticals |
Phenylephrine hydrochloride (Vazculep®) - Summary of Product Characteristics |
|
3772 |
Janssen Biotech |
Siltuximab (Sylvant®) - Summary of Product Characteristics |
|
3773 |
Eli Lilly |
Ramicirumab (Cyramza®) - Summary of Product Characteristics |
|
3774 |
Amgen |
Blinatumomab - (Blincyto®) - Summary of Product Characteristics |
|
3775 |
Talon Therapeutics |
Vincristine sulfate liposome (Marqibo®) - Summary of Product Characteristics |
|
3776 |
Teva Pharmaceuticals |
Omecetaxine (Synribo®) - Summary of Product Characteristics |
|
3787 |
The Medicines Company |
Oritavancin diphosphate (Orbactiv®) - Summary of Product Characteristics |
|
3803 |
Laboratoires Merck Sharp & Dohme Chibret |
Ceftolozane / tazobactam (Zerbaxa®) - Summary of Product Characteristics |
|
3818 |
Pharmaceutical Technology in Hospital Pharmacy |
Stability of 25 mg/mL 5-azacitidine suspension kept in fridge after freezing. |
|
3838 |
Martindale Pharmaceuticals Ltd |
Magnesium Sulphate - Summary of Product Characteristics |
|
3850 |
Eur J Cancer |
Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues. |
|
3861 |
J Pharm Pract and Res |
Evaluation of stability of melatonin in extemporaneously compounded oral suspensions. |
|
3869 |
J Pharm Pharmacol |
Influence of 5% dextrose volume on amphotericin B deoxycholate preparation |
|
3880 |
Int J Pharm Compound |
Stability of Ampicillin in Normal Saline and Buffered Normal Saline. |
|
3883 |
Arrow |
Ceftazidime - Résumé des caractéristiques du produit |
|
3888 |
Perit Dial Int |
Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). |
|
3892 |
Can J Hosp Pharm |
Stability of Hydrocortisone, Nifedipine, and Nitroglycerine Compounded Preparations for the Treatment of Anorectal Conditions |
|
3893 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Amlodipine Besylate Oral Suspensions |
|
3902 |
Int J Pharm Compound |
Stability of Allopurinol, Amitriptyline Hydrochloride, Carbamazepine, Domperidone, Isoniazid, Ketoconazole, Lisinopril, Naproxen, Paracetamol (Acetaminophen), and Sertraline Hydrochloride in SyrSpend SF PH4 Oral Suspensions. |
|
3903 |
Int J Pharm Compound |
Stability of Sodium Nitroprusside in 5% Dextrose Stored at 4°C in Polypropylene Syringes Protected from Light. |
|
3918 |
J Oncol Pharm Practice |
Compatibility of epirubicin-loaded DC bead™ with different non-ionic contrast media. |
|
3920 |
Fresenius Kabi |
Levofloxacine - Résumé Caractéristique du Produit |
|
3921 |
Can J Hosp Pharm |
Stability of extemporaneously prepared enalapril maleate suspensions in glass bottles and plastic syringes. |
|
3930 |
Serb laboratoire |
Indocyanine (Infracyanine®) - Résumé des caractéristiques du produit |
|
3931 |
Pfizer Laboratoire |
Trimébutine (Débridat®) - Résumé des caractéristiques du produit |
|
3932 |
Serb Laboratoire |
Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit |
|
3933 |
Teva Laboratoire |
Acide zolédronique - (Acide zoledronique Teva Pharma) - Résumé des caractéristiques du produit |
|
3934 |
GlaxoSmithKline Laboratoire |
Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit |
|
3935 |
Sanofi Laboratoire |
Insuline glulisine (Insulines Sanofi Apidra®) - Résumé des caractéristiques du produit |
|
3936 |
GlaxoSmithKline Laboratoire |
Bélimumab (Benlysta®) – Résumé des caractéristiques du produits |
|
3938 |
Lilly S.A |
Necitumumab (Portrazza®) – Résumé des caractéristiques du produits |
|
3941 |
Concordia International |
Nicardipine - Summary of Product Characteristics |
|
3946 |
Can J Hosp Pharm |
Stability of Extemporaneously Compounded Tacrolimus in Glass Bottles and Plastic Syringes |
|
3949 |
JFSPH Congress, Bern, Switzerland. |
Optimisation du processus de préparation des solutions de melphalan destinées à l’administration intra-vitréenne dans le traitement du rétinoblastome et étude de leur stabilité |
|
3968 |
Fresenius Kabi |
Ringer lactate - Résumé des Caractéristiques du Produit |
|
3978 |
Am J Health-Syst Pharm |
Beyond-use dating of lidocaine alone and in two “magic mouthwash” preparations. |
|
3992 |
Int J Pharm |
Formulation and charaterization of 0,1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas. |
|
4004 |
Krankenhauspharmazie |
Physikalisch-chemische Stabilität von Oxaliplatin-beta-Infusionslösungskonzentrat und Infusionslösungen in 5 % Glucose in Polyolefin-Infusionsbeuteln. |
|
4009 |
Panpharma |
Droperidol - Résumé des Caractéristiques du Produit |
|
4022 |
Am J Health-Syst Pharm |
Stability of extemporaneously prepared rosuvastatin oral suspension. |
|
4023 |
Hosp Pharm |
Compounded Apixaban Suspensions for Enteral Feeding Tubes. |
|
4040 |
J Oncol Pharm Practice |
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion. |
|
4050 |
Pharmaceutical Technology in Hospital Pharmacy |
Preparation and physico-chemical stability of dexamethasone oral suspension. |
|
4063 |
Int J Pharm Compound |
Stability of an Alcohol-free, Dye-free Hydrocortisone (2mg/mL) Compounded Oral Suspension. |
|
4065 |
Mylan |
Urapidil (Eupressyl® - résumé des caractéristiques du produit) |
|
4068 |
|
Natalizumab (Tysabri®) - Summary of Product Characteristics |
|
4070 |
Hosp Pharm |
Stability of 2 mg/mL Adenosine Solution in Polyvinyl Chloride and Polyolefin Infusion Bags. |
|
4079 |
J Pharm Anal |
Formulation, stability testing, and analytical characterization of melatonin-based preparation for clinical trial. |
|
4084 |
Accord Health Care |
Cisplatine - Résumé des caractéristiques du produits |
|
4086 |
Novartis Pharma |
Octréotide - (Sandostatine®)- Résumé des caractéristiques du produit |
|
4096 |
Pharm Dev Technol |
Physicochemical stability of a new topical timolol 0.5% gel formulation for the treatment of infant hemangioma. |
|
4121 |
Int J Pharm Compound |
The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia. |
|
4122 |
Hosp Pharm |
Stability of Meropenem After Reconstitution for Administration by Prolonged Infusion. |
|
4140 |
Int J Pharm Compound |
Comparative Stability of Vitamin K1 Oral Liquids Prepared in Sterile Water for Injection and Stored in Amber Glass Bottles and Amber Plastic Syringes. |
|
4153 |
Orphan Europe (UF) Limited |
Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics |
|
4154 |
Accord Health Care |
Bleomycin sulfate- Summary of Product Characteristics |
|
4157 |
Pediatric Anesthesia |
Evaluation of the stability and stratification of propofol and ketamine mixtures for pediatric anesthesia. |
|
4173 |
Baxalta Innovations GmbH |
Pegaspargase (Oncaspar®) - Résumé des Caractéristiques du Produit |
|
4190 |
Janssen |
Daratumumab (Darzalex®) - Summary of Product Characteristics. |
|
4194 |
Bio Drugs |
In-Use Physichochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion. |
|
4256 |
Pharmaceutics |
Preparation and Physicochemical Stability of Liquid Oral Dosage Forms Free of Potentially Harmful Excipient Designed for Pediatric Patients. |
|
4264 |
Acta Ophtalmol |
Stability and antibacterial potency of ceftazidime and vancomycin eyedrops reconstituted in BSS against Pseudomonas aeruginosa and Staphylococcus aureus. |
|
4279 |
Bio Drugs |
Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA). |
|
4289 |
Photochemical & Photobiological Sciences |
Stability and degradation of indocyanine green in plasma, aqueous solution and whole blood. |
|
4292 |
Drugs R D |
Assessing the Extended In-Use Stability of the Infliximab Biosimilar PF-06438179/GP1111 Following Preparation for Intravenous Infusion. |
|
4293 |
J Pharm Pract and Res |
Validation of the stability of paracetamol in extemporaneously compounded suppositories. |
|
4313 |
PlosOne |
Stability of Diazoxide in Extemporaneously Compounded Oral Suspensions. |
|
4317 |
J Pharm Technol |
Comparative Stability of Oral Vitamin K Liquids Stored in Refrigerated Amber Plastic Syringes. |
|
4334 |
J Oncol Pharm Practice |
Physicochemical stability of pembrolizumab admixture solution in normal saline intravenous infusion bag. |
|
4355 |
Jazz Pharmaceuticals UK |
Daunorubicine/cytarabine liposomale (Vyxeos®) - Summary of Product Characteristics |
|
4362 |
EJHP |
Physicochemical stability of binary admixtures of paracetamol and dexketoprofen-trometamol for patient-controlled analgesia use. |
|
4377 |
Radiology |
Ionic lodinated Contrast Medium and Amobarbital Sodium Mixtures: Potential for Precipitation. |
|
4380 |
Merck Sharp & Dohme Limited |
Posaconazole (Noxafil®) - Summary of Product Characteristics |
|
4398 |
J Pharm Pract and Res |
Compatibility of intravenous busulfan with BBraun giving sets, fludarabine and Posiflush. |
|
4455 |
J Oncol Pharm Practice |
Physical and chemical stability of cytarabine in polypropylene syringes. |
|
4467 |
Roche Products Limited |
Avastin - Summary of Product Characteristics |
|
4471 |
Kyowa Kirin Pharma |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 |
|
4474 |
Merck |
Avelumab (Bavencio®) - Summary of Product Characteristics |
|
4477 |
GaBI Journal |
Stability of the trastuzumab biosimilar ABP 980 compared to reference product after intravenous bag preparation, transport and storage at various temperatures, concentration and stress conditions. |
|
4491 |
Eur J Pedia |
Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. |
|
4492 |
Int J Antimicrob Agents |
Preparation and physicochemical stability of 50 mg/ml hydroxychloroquine oral suspension in Syrspend pH4 dry. |
|
4503 |
RIEMSER Pharma GmbH |
Ziconotide (Prialt®) - Summary of Product Characteristics |
|
4505 |
Eur J Cancer |
Stability of nivolumab in its original vials after opening and handing in normal saline bag for intravenous infusion. |
|
4516 |
GaBI Journal |
Physicochemical stability of the bevacizumab biosimilar, ABP 215, after preparation and storage in intravenous bags. |
|
4532 |
Roche Products Limited |
Atezolizumab (Tecentriq®) - Summary of Product Characteristics |
|
4538 |
Archives of Disease in Childhood |
Compatibility of pentoxifylline and parenteral medications. |
|
4543 |
Archives of Disease in Childhood |
Physical compatibility of pentoxifylline and intravenous medications. |
|
4571 |
Orion Pharma |
Levosimendan (Simdax 2.5 mg/ml) - Summary of Product Characteristics |
|
4573 |
Am J Health-Syst Pharm |
Long-term physicochemical stability of acyclovir 5 mg/mL solution stored in polypropylene bags as a simulated hospital stock preparation. |
|
4582 |
J Pharm Technol |
Beyond-Use Dates Assignment for Pharmaceutical Preparations: Example of Low-Dose Amiodarone Capsules. |
|
4589 |
Viatris |
Pemetrexed Viatris- Résumé des caractéristiques du produit |
|
4606 |
Int J Pharm Compound |
Study on the Optimal Conditions for Long-term Storage of Melatonin Powder as an In-hospital Preparation. |
|
4608 |
Astra Zeneca |
Durvalumab (Imfinzi - Summery of Product Characteristics, updated August 2021) |
|
4611 |
J Pharm Anal |
Use of subcutaneous tocilizumab to prepare intravenous solutions for COVID-19 emergency shortage: Comparative analytical study of physicochemical quality attributes. |
|
4612 |
OFIL |
Estabilidad de la solución de gentamicina y heparina para sellado de catéter. |
|
4616 |
Pharmaceutics |
Stability of Hydrocortisone in Oral Powder Form Compounded for Pediatric Patients in Japan. |
|
4617 |
Sanofi Genzyme |
Isatuximab - SARCLISA 20mg/mL concentrate for solution for infusion - Summary of Product Characteristics - updated 16 August 2021 |
|
4629 |
|
Pemetrexed Sandoz - Summary of Product Characteristics (SmPc) |
|
4630 |
J Pharm Health Care Sci |
Stability of clonidine hydrochloride in an oral powder form compounded for pediatric patients in Japan. |
|
4637 |
Braz J Pharm Sci |
Evaluation of physicochemical and microbiological stability of liquid preparation from tizanidine hydrochloride tablets - a Hospital concern. |
|
4650 |
Advanz Pharma |
Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. |
|
4652 |
Bristol Myers Squibb Pharmaceuticals |
Nivolumab (Opdivo®) - Summary of Product Characteristics |
|
4665 |
Sanofi Aventis |
LEMTRADA 12 mg concentrate for solution for infusion - Summary of Product Characteristics. Updated 24-Sep-2021 |
|
4675 |
Pharmaceuticals |
Simple Approach to Enhance Green Tea Epigallocatechin Gallate Stability in Aqueous Solutions and Bioavailability: Experimental and Theoretical Characterizations. |
|
4679 |
PlosOne |
Stability of extemporaneously prepared sitagliptin phosphate solution. |
|
4686 |
Roche Products Ltd. |
Pertuzumab (Perjeta®) - Summary of Product Characteristics. |
|
4691 |
Int J Pharm Compound |
Physical and Chemical Stability of Pharmaceutical Preparation of Bumetanide and Scopolamine. |
|
4700 |
AS Kalceks |
Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics |
|
4717 |
|
Enhertu®- Résumé des caractéristiques du produit |
|
4719 |
SAGE Open Medicine |
Prepared omadacycline for injection: Nine-day stability and sterility in an elastomeric pump. |
|
4720 |
Paratek Pharmaceuticals |
Nuzyra (omadacycline - Full prescribing infomation. Paratek Pharmaceuticals updated May 2021. |
|
4726 |
Mylan |
Arsenic trioxide Mylan - Résumé des caractéristiques du produit |
|
4729 |
Pharmaceutics |
Extemporaneous Preparation of 20 mg/mL Ganciclovir in Artificial Tears in Comparison with SterileWater for Ophthalmic Administration: Formulation and Stability Study. |
|
4740 |
Roche Products Limited |
MabThera 500 mg concentrate for solution for infusion. Summary of Product Characteristics Updated 07-Oct-2021 |
|
4741 |
Int J Pharm Compound |
Physicochemical and Microbiological Stability of Pyrimethamine in Paraben-free PCCA Base,
SuspendIt. |
|
4754 |
J Oncol Pharm Practice |
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions. |
|
4756 |
J Oncol Pharm Practice |
Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions. |
|
4763 |
Pharmaceutical Technology in Hospital Pharmacy |
Physicochemical stability of urea-containing Mitomycin C preparations in glass vials (1.0 mg/mL) and plastic syringes (2.0, 0.4, 0.2 mg/mL) |
|
4770 |
Pharmaceutical Technology in Hospital Pharmacy |
Use of a liquid chromatography-tandem mass spectrometry method to assess the concentration of epinephrine, norepinephrine, and phenylephrine stored in plastic syringes. |
|
4771 |
J Pharm Technol |
Stability of Olmesartan Medoxomil Extemporaneous Suspensions. |
|
4784 |
EJHP |
In-use stability of ready-to- administer daratumumab subcutaneous injection solution in plastic syringes. |
|
4785 |
Janssen-Cilag International NV |
Darzalex 1800 mg solution for injection - Summary of Product characteristics. |
|
4789 |
Braz J Pharm Sci |
Stability of sulfadiazine sugar-free oral suspensions for the treatment of congenital toxoplasmosis. |
|
4802 |
Aguettant Laboratory |
Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit |
|
4807 |
Amgen Ltd |
Vectibix 20 mg/mL concentrate for solution for infusion. Summary of Product Characteristics Updated 13-Jul-2023 |
|
4808 |
Hosp Pharm |
Characterizing the Stability of Angiotensin II in 0.9% Sodium Chloride Using High Performance Liquid Chromatography and Liquid Chromatography Tandem Mass Spectrometry. |
|
4809 |
|
Recarbrio® - Résumé des caractéristiques du produit |
|
4810 |
|
Libtayo® - Résumé des caractéristiques du produit |
|
4813 |
Int J Pharm Compound |
Compatibility of Various Hormones in Phytobase and HRT Heavy Cream Bases |
|
4818 |
PAION UK Ltd |
Giapreza 2.5mg per ml concentrate for solution for infusion - Summary of Product Characteristics Updated 30-Jun-2022 |
|
4819 |
Int J Pharm |
Prolonging the stability of cetuximab (Erbitux®) and panitumumab (Vectibix®): An orthogonal assessment of physicochemical, biological and microbiological properties of original opened glass vials and diluted saline preparations. |
|
4821 |
Pharmaceutics |
AmBisome® Formulations for Pediatrics: Stability, Cytotoxicity, and Cost-Effectiveness Studies. |
|
4852 |
Merck Sharp & Dohme B.V. |
KEYTRUDA 25 mg/mL solution à diluer pour perfusion. Résumé des caractéristiques du produit. |
|
4862 |
Porton Biopharma Limited |
Erwinase, 10,000 IU/vial, Powder for solution for injection/infusion - Summary of Product Characteristics Updated 04-Jul-2022. |
|
4865 |
Dr REDDY laboratoire |
Cyclophosphamide REDDY PHARMA 2000 mg/4 ML, solution à diluer pour solution injectable/perfusion. - Résumé des caractéristiques du produit. |
|
4884 |
Int J Pharm Compound |
Stability of Diluted Desmopressin Acetate Intranasal Solution at 0.01 mg/mL. |
|
4887 |
Astra Zenaca AB |
IMJUDO (tremelimumab) 20 mg/mL concentrate for solution for infusion. Summary of Product Characteristics. |
|
4905 |
Pharmaceuticals |
Characterization of Liquid Dosage Forms of Atenolol and Enalapril Maleate for Oral and Enteral Feeding Administration |
|
4911 |
|
Glofitamab (Columvi®) - Résumé des caractéristiques du produit |
|
4912 |
Incyte Biosciences |
Tafasitamab (Minjuvi®) - Résumé des caractéristiques du produit |
|
4913 |
Janssen-Cilag International NV |
Teclistamab (Tecvayli®) - Résumé des caractéristiques du produit |
|
4919 |
|
Dostarlimab (Jemperli®) – Résumé des caractéristiques du produits |
|
4924 |
EJHP |
Physical compatibility of lipid emulsions and intravenous medications used in neonatal intensive care settings |
|
4927 |
GERPAC Congress |
Préparation d'étoposide injectable concentrée à 10 mg/mL : intérêts et stabilité physicochimique. |
|
4929 |
Int J Pharm Compound |
Long-term Physicochemical Stability of a Pharmaceutical Preparation of Morphine Hydrochloride and Droperidol in Polypropylene Syringes. |
|
4945 |
Colonis Pharma Ltd |
Iloprost 100 micrograms/ml concentrate for solution for infusion - Summary of Product Characteristics Updated 12-Oct-2023. |
|
4950 |
Pfizer Europe MA EEIG |
Emblaveo 1,5 g/0,5 g, poudre pour solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4951 |
PANMEDICA |
ACIDE ACETYLSALICYLIQUE PANPHARMA 1 g, poudre et solvant pour solution injectable - Résumé des caractéristiques du produit - Mise à jour 19/09/2024. |
|
4952 |
Hameln pharma ltd |
Alfentanil 5 mg/ml solution for injection - Summary of Product Characteristics Updated 19-Oct-2022 | hameln pharma ltd |
|
4953 |
SANOFI WINTHROP |
PLITICAN, solution injectable - Résumé des caractéristiques du produit |
|
4954 |
INTSEL CHIMOS |
ALPROSTADIL INTSEL CHIMOS 0,5 mg/ml, solution injectable - Résumé des caractéristiques du produit |
|
4958 |
SANOFI B.V. |
THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion - Résumé des caractéristiques du produit. |
|
4959 |
EVER VALINJECT GMBH |
ATOSIBAN EVER PHARMA 75 mg/10 mL, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4960 |
ASPEN PHARMA TRADING LIMITED |
IMUREL 50 mg, poudre pour solution injectable (IV) - Résumé des caractéristiques du produit. |
|
4961 |
Baxter Healthcare Ltd |
Bupivacaine 2.5mg/ml Solution for Injection - Summary of Product Characteristics Updated 21-Mar-2024. |
|
4963 |
ACCORD HEALTHCARE FRANCE |
BUSULFAN ACCORD 6 mg/mL, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4964 |
B BRAUN MELSUNGEN AG |
GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit. |
|
4965 |
ACCORD HEALTHCARE FRANCE SAS |
CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion - Résumé des caractéristiques du produit. |
|
4966 |
PANPHARMA |
CEFAZOLINE PANPHARMA 1 g, poudre pour solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
4967 |
Renascience Pharma Ltd |
Renoxitin 1g Powder for solution for injection or Infusion - Summary of Product Characteristics Updated 21-Mar-2025. |
|
4968 |
Pfizer Limited |
Zinforo 600 mg powder for concentrate for solution for infusion - Summary of Product Characteristics Updated 06-Jun-2024. |
|
4969 |
Essential Pharma Ltd |
Chloramphenicol 1 g Powder for Injection - Summary of Product Characteristics Updated 21-Jan-2025. |
|
4970 |
TILLOMED PHARMA GMBH |
CIDOFOVIR TILLOMED 75 mg/mL solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4972 |
CHEPLAPHARM ARZNEIMITTEL GMBH |
RIVOTRIL 1 mg/1 ml, solution à diluer injectable en ampoules - Résumé des caractéristiques du produit. |
|
4973 |
GLENWOOD GMBH |
CATAPRESSAN 0,15 mg/ml, solution injectable - Résumé des caractéristiques du produit. |
|
4974 |
PANPHARMA |
CLOXACILLINE PANPHARMA 1 g, poudre pour solution injectable (I.V.) - Résumé des caractéristiques du produit. |
|
4975 |
Teva UK Limited |
Colomycin 1 million International Units (IU) Powder for solution for injection, infusion orinhalation
Summary of Product Characteristics Updated 12-Jul-2023. |
|
4976 |
PFIZER HOLDING FRANCE |
FRAGMINE 10 000 U.I. anti-Xa/0,4 mL, solution injectable en seringue pré-remplie - Résumé des caractéristiques du produit. |
|
4981 |
MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. |
KETESSE 50 mg/2 ml, solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
4982 |
Wockhardt UK Ltd |
Diamorphine Hydrochloride 100mg for Injection - Summary of Product Characteristics Updated 06-May-2020. |
|
4983 |
|
DIAZEPAM RENAUDIN 10 mg/2 ml, solution injectable - Résumé des caractéristiques du produit. |
|
4984 |
GLENWOOD GMBH |
PERSANTINE 10 mg/2 mL, solution injectable en ampoule - Résumé des caractéristiques du produit. |
|
4985 |
ARROW GENERIQUES |
ENOXAPARINE ARROW 10 000 UI (100 mg)/1 mL, solution injectable en seringue préremplie - Résumé des caractéristiques du produit. |
|
4986 |
Fresenius Kabi France SA |
FLUCONAZOLE KABI 2 mg/ml, solution pour perfusion - Résumé des caractéristiques du produit. |
|
4987 |
TILLOMED PHARMA GMBH |
MILRINONE TILLOMED 1 mg/mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
4990 |
LABORATOIRE AGUETTANT |
NORADRENALINE (TARTRATE) AGUETTANT 2 mg/ml (SANS SULFITES), solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
4991 |
B BRAUN MELSUNGEN |
GRANISETRON B BRAUN 3 mg/3 ml, solution à diluer injectable ou pour perfusion - Résumé des caractéristiques du produit. |
|
4992 |
MACURE HEALTHCARE LTD. |
LORAZEPAM XILMAC 4 mg/mL, solution injectable - Résumé des caractéristiques du produit. |
|
4993 |
ASPEN PHARMA TRADING LIMITED |
MIVACRON 20 mg/10 ml, solution injectable (IV) - Résumé des caractéristiques du produit. |
|
4994 |
LABORATOIRE AGUETTANT |
KETOPROFENE AGUETTANT 100 mg, solution pour perfusion - Résumé des caractéristiques du produit. |
|
4995 |
EUGIA PHARMA (MALTA) LTD |
PANTOPRAZOLE ARROW 40 mg, poudre pour solution injectable (IV) - Résumé des caractéristiques du produit. |
|
4996 |
ALTAN PHARMA LTD |
NIMODIPINE ALTAN 10 mg/50 mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
4997 |
VIATRIS SANTÉ |
NALOXONE VIATRIS 0,4 mg/1 ml, solution injectable en ampoule - Résumé des caractéristiques du produit. |
|
4998 |
MITEM PHARMA |
PROPRANOLOL ACETLAB 5 mg/5 mL, solution injectable - Résumé des caractéristiques du produit. |
|
4999 |
PFIZER HOLDING FRANCE |
NIPENT 10 mg, poudre pour solution pour injection, poudre pour solution pour perfusion - Résumé des caractéristiques du produit. |
|
5000 |
PANPHARMA |
OXYTOCINE PANPHARMA 5 UI/1 ml, solution injectable - Résumé des caractéristiques du produit. |
|
5004 |
TEVA B.V. |
NEFOPAM TEVA 20 mg/2 mL, solution injectable - Résumé des caractéristiques du produit. |
|
5005 |
LABORATOIRE RENAUDIN |
QUININE RENAUDIN 245 mg/ml, solution injectable pour perfusion IV - Résumé des caractéristiques du produit. |
|
5006 |
TEVA SANTE |
SPASFON, solution injectable en ampoule - Résumé des caractéristiques du produit. |
|
5007 |
EUGIA PHARMA (MALTA) LTD |
LEVETIRACETAM ARROW LAB 100 mg/mL, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5008 |
CHEPLAPHARM ARZNEIMITTEL GMBH |
CYMEVAN 500 mg, poudre pour solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5009 |
SUBSTIPHARM |
HYDROCORTISONE SUBSTIPHARM 100 mg, lyophilisat (flacon) et solution pour usage parentéral - Résumé des caractéristiques du produit. |
|
5010 |
CHUGAI PHARMA FRANCE |
GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion en seringue préremplie - Résumé des caractéristiques du produit. |
|
5011 |
Piramal Critical Care Limited |
Hypnomidate 2 mg/ml Injection - Summary of Product Characteristics Updated 02-Apr-2024. |
|
5012 |
LABORATOIRES CHAIX ET DU MARAIS |
CHLORURE DE MAGNESIUM 10 POUR CENT (1 g/10 ml) LAVOISIER, solution injectable (I.V.) en ampoule - Résumé des caractéristiques du produit. |
|
5013 |
VIFOR FRANCE |
FERINJECT 50 mg/mL, dispersion injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
5014 |
TILLOMED PHARMA GMBH |
TREPROSTINIL TILLOMED 5 mg/mL, solution pour perfusion - Résumé des caractéristiques du produit. |
|
5015 |
LABORATOIRE RENAUDIN |
SUFENTANIL RENAUDIN 50 microgrammes/mL, solution injectable (IV ou péridurale) - Résumé des caractéristiques du produit. |
|
5016 |
Tillomed Laboratories Ltd |
Tranexamic Acid 100 mg/ml Solution for Injection - Summary of Product Characteristics Updated 25-Mar-2025. |
|
5017 |
A. Menarini Farmaceutica Internazionale SRL |
Vaborem 1 g/1 g powder for concentrate for solution for infusion - Summary of Product Characteristics Updated 22-Aug-2024. |
|
5018 |
AS KALCEKS |
SCOPOLAMINE BUTYLBROMURE KALCEKS 20 mg/mL, solution injectable - Résumé des caractéristiques du produit. |
|
5020 |
SERB Laboratory |
TIBERAL 1 g, solution injectable pour perfusion - Résumé des caractéristiques du produit. |
|
5021 |
SERB Laboratory |
L-THYROXINE SERB 200 microgrammes/mL, solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
5022 |
Pharmacosmos A/S |
CosmoFer 50mg/ml solution for infusion and injection - Summary of Product Characteristics. |
|
5024 |
PFIZER |
LINCOCINE 600 mg, solution injectable, B/1/2ml - Résumé des caractéristiques du produit. |
|
5026 |
Gilead Sciences Ireland UC |
Veklury 100 mg poudre pour solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5027 |
Almirall, S.A. |
Meptid 100 mg/ml Solution for Injection - Summary of Product Characteristics. |
|
5028 |
TAKEDA PHARMA A/S |
XEFO 8 mg, poudre et solvant pour solution injectable - Résumé des caractéristiques du produit. |
|
5029 |
Teva Pharma Belgium S.A. |
VoriNa 25 mg/ml solution injectable - Résumé des caractéristiques du produit. |
|
5030 |
Viatris |
FLECAINE 10 mg/ml, solution injectable - Résumé des caractéristiques du produit. |
|
5031 |
Akorn Operating Company |
IntravenousSodium Diuril® ) - Summary of Product Characteristics. |
|
5032 |
SERB |
VIBRAVEINEUSE, solution injectable pour voie IV et perfusion - Résumé des caractéristiques du produit. |
|
5035 |
Xellia Pharmaceuticals |
POLYMYXIN B for INJECTION, USP500,000 Units/vial - Summary of Product Characteristics. |
|
5037 |
EG LABO - LABORATOIRES EUROGENERICS |
VELBE 10 mg, poudre pour solution injectable I.V. - Résumé des caractéristiques du produit. |
|
5038 |
Tillomed Laboratories Limited |
Treosulfan 5g Powder for Solution for Infusion - Summary of Product Characteristics Updated 06-Dec-2024. |
|
5039 |
Novo Nordisk A/S |
Esperoct powder and solvent for solution for injection - Summary of Product Characteristics. |
|
5040 |
B BRAUN MELSUNGEN AG |
CHLORURE DE POTASSIUM B. BRAUN 10 % (0,10 g/ml), solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5042 |
Orion Corporation |
Dexdor 100 micrograms/ml concentrate for solution for infusion - Summary of Product Characteristics. |
|
5043 |
Genta Incorporated |
GANITE- gallium nitrate injection, s olution, concentrate - Summary of Product Characteristics. |
|
5044 |
Novo Nordisk A/S |
Actrapid 100 unités internationales/ml, solution injectable en flacon. - Résumé des caractéristiques du produit. |
|
5045 |
Eli Lilly |
Humalog 100 UI/ml, solution injectable en flacon - Résumé des caractéristiques du produit. |
|
5046 |
Global Harvest Pharmaceuticals |
Metaraminol 10 mg/ml Solution for Injection or Infusion - Package leaflet: Information for the user. |
|
5047 |
Roche |
CellCept 500 mg poudre pour solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5049 |
Namigen |
Sodium Nitroprusside Injection - Summary of Product Characteristics. |
|
5053 |
LABORATOIRE RENAUDIN |
PHOSPHATE MONOPOTASSIQUE RENAUDIN 136,10 mg/ml, solution pour perfusion - Résumé des caractéristiques du produit. |
|
5054 |
POLİFARMA İLAÇ SAN. VE TİC. A.Ş. |
POLTEOFİLİN 400 MG/500 ML INJECTABLE SOLUTION FOR I.V. INFUSION - Summary of Product Characteristics. |
|
5055 |
Roche |
RoActemra 20 mg/mL concentrate for solution for infusion - Résumé des caractéristiques du produit. |
|
5057 |
EUMEDICA PHARMACEUTICALS GMBH |
ACTOSOLV 600 000 UI, poudre pour solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
5058 |
Melinta Therapeutics, |
MINOCIN®, Minocycline For Injection - Summary of Product Characteristics. |
|
5060 |
ADVANZ Pharma |
Lidocaine Hydrochloride Injection B.P. 1.0% w/v - Summary of Product Characteristics Updated 09-Nov-2023 |
|
5062 |
ADVANZ Pharma |
Hydralazine 20mg Powder for Concentrate for Solution for Injection/Infusion - Summary of Product Characteristics Updated 09-Sep-2024 |
|
5066 |
Bowmed Ibisqus Limited |
Meropenem 500mg powder for solution for injection/ infusion - Summary of Product Characteristics Updated 21-Aug-2024. |
|
5067 |
PFIZER HOLDING FRANCE |
UNACIM INJECTABLE 0,5 g/1 g, poudre pour usage parentéral - Résumé des caractéristiques du produit. |
|
5068 |
ACINO FRANCE SAS |
ABELCET 5 mg/ml, suspension à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5069 |
LABORATOIRE AGUETTANT |
MORPHINE (CHLORHYDRATE) AGUETTANT 10 mg/mL, solution injectable - Résumé des caractéristiques du produit. |
|
5071 |
LABORATOIRE AGUETTANT |
FOLINATE DE CALCIUM AGUETTANT 100 mg, poudre pour solution injectable - Résumé des caractéristiques du produit. |
|
5073 |
Napp Pharmaceuticals Limited |
Palladone 10 mg/ml solution for injection or infusion - Summary of Product Characteristics Updated 28-Apr-2025. |
|
5074 |
EUGIA PHARMA (MALTA) LTD |
FOSPHENYTOINE ARROW 75 mg/mL, solution à diluer pour solution injectable/pour perfusion - Résumé des caractéristiques du produit. |
|
5075 |
ACCORD HEALTHCARE FRANCE SAS |
IDARUBICINE ACCORD 5 mg/5 ml, solution pour perfusion - Résumé des caractéristiques du produit. |
|
5076 |
Panmedica |
AMIKACINE PANPHARMA 250 mg/mL, solution injectable - Résumé des caractéristiques du produit. |
|
5077 |
VIATRIS SANTE |
ETOPOSIDE VIATRIS 20 mg/ml, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
|
5086 |
Hospira UK Limited |
Tobramycin 40mg/ml Solution for Injection - Summary of Product Characteristics Updated 29-Feb-2024 | Hospira UK Ltd |
|
5087 |
ALFASIGMA FRANCE |
ANAFRANIL 25 mg/2 ml, solution injectable - Résumé des caractéristiques du produit. |
|
5088 |
Chemidex Pharma Limited |
Ampicillin 500 mg powder for solution for injection - Summary of Product Characteristics Updated 04-Feb-2025 | Chemidex Pharma Ltd |
|
5089 |
Phoenix Labs |
Ascorbic Acid Injection 500mg/5ml - Summary of Product Characteristics Updated 04-Jan-2024 | Phoenix Labs |
|
5090 |
Sanofi |
TILDIEM 25 mg, poudre et solution pour préparation injectable I.V. - Résumé des caractéristiques du produit. |
|
5091 |
PHARMHOLDING SA |
RIMIFON 500 mg/5 ml, solution injectable / pour perfusion - Résumé des caractéristiques du produit. |
|
5092 |
ZENTIVA FRANCE |
LEVOFOLINATE DE CALCIUM ZENTIVA 25 mg/2,5ml, solution injectable (IM/IV) - Résumé des caractéristiques du produit. |
|
5093 |
ACCORD HEALTHCARE FRANCE SAS |
FUROSEMIDE ACCORD 20 mg/2 ml, solution injectable - Résumé des caractéristiques du produit. |
|
5094 |
LUNDBECK SAS |
SEROPRAM 20 mg/0,5 ml, solution à diluer pour perfusion - Résumé des caractéristiques du produit. |
Search
